IGC Pharma launches Holiby wellness brand

IGC Pharma (IGC) announced the launch of Holiby, a wellness brand offering scientifically formulated products for immune defense and sustained energy. This strategic expansion into the rapidly growing $75 billion wellness industry establishes a new revenue stream while IGC Pharma continues advancing its pharmaceutical pipeline focused on treatments for Alzheimer’s disease and metabolic disorders. IGC will leverage its existing capacity at its state-of-the-art manufacturing facilities in Washington State – originally established for pharmaceutical production – to manufacture and distribute Holiby’s over-the-counter wellness products and formulations. This duel strategy creates near-term revenue growth and maximizes operational efficiencies while the company advances IGC-AD1 through its Phase 2 and Phase 3 clinical trials and further develops promising metabolic drug candidates. Holiby products will be available for direct-to-consumer online sales and white-label partnerships with wellness brands, further expanding revenue opportunities.